Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Purchased by Peregrine Capital Management LLC

Peregrine Capital Management LLC grew its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 1.8% during the fourth quarter, Holdings Channel reports. The firm owned 244,043 shares of the company’s stock after acquiring an additional 4,361 shares during the quarter. Peregrine Capital Management LLC’s holdings in Kiniksa Pharmaceuticals were worth $4,827,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in KNSA. Braidwell LP lifted its stake in Kiniksa Pharmaceuticals by 40.6% during the third quarter. Braidwell LP now owns 2,894,513 shares of the company’s stock worth $72,334,000 after purchasing an additional 836,210 shares in the last quarter. FMR LLC lifted its stake in Kiniksa Pharmaceuticals by 36,925.0% during the third quarter. FMR LLC now owns 696,810 shares of the company’s stock worth $17,413,000 after purchasing an additional 694,928 shares in the last quarter. Jane Street Group LLC lifted its stake in Kiniksa Pharmaceuticals by 1,064.4% during the third quarter. Jane Street Group LLC now owns 345,092 shares of the company’s stock worth $8,624,000 after purchasing an additional 315,456 shares in the last quarter. JPMorgan Chase & Co. acquired a new position in Kiniksa Pharmaceuticals during the third quarter worth $4,997,000. Finally, Castleark Management LLC acquired a new position in Kiniksa Pharmaceuticals during the third quarter worth $4,178,000. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals Price Performance

NASDAQ:KNSA opened at $19.66 on Thursday. The firm has a market capitalization of $1.42 billion, a PE ratio of -140.42 and a beta of 0.32. The business’s fifty day moving average price is $19.72 and its 200 day moving average price is $22.74. Kiniksa Pharmaceuticals, Ltd. has a 12 month low of $16.56 and a 12 month high of $28.15.

Insider Activity at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, CFO Mark Ragosa sold 8,969 shares of the company’s stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $21.45, for a total value of $192,385.05. Following the completion of the transaction, the chief financial officer now owns 22,958 shares in the company, valued at $492,449.10. This represents a 28.09 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Eben Tessari sold 14,000 shares of the company’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $18.24, for a total transaction of $255,360.00. Following the completion of the transaction, the chief operating officer now owns 88,975 shares of the company’s stock, valued at $1,622,904. This represents a 13.60 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 38,092 shares of company stock valued at $745,589 over the last quarter. 54.57% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Evercore ISI upped their price objective on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. JPMorgan Chase & Co. upped their price objective on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Finally, Wedbush reaffirmed an “outperform” rating and set a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research report on Monday, January 13th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $36.60.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.